Jerry Avorn1. Show Affiliations » 1. Harvard Medical School, Boston, USA.
Abstract
Mesh: See more » Cannabinoids/antagonists & inhibitorsDexfenfluramine/adverse effectsDexfenfluramine/therapeutic useDrug Approval/legislation & jurisprudenceHumansObesity/drug therapyPiperidines/adverse effectsPyrazoles/adverse effectsRimonabantSleep Initiation and Maintenance Disorders/drug therapyUnited StatesUnited States Food and Drug Administration/legislation & jurisprudenceUnited States Food and Drug Administration/standards
Substances: See more » CannabinoidsPiperidinesPyrazolesDexfenfluramineRimonabant
Year: 2005 PMID: 16148281 DOI: 10.1056/NEJMp058174
Source DB: PubMed Journal: N Engl J Med ISSN: 0028-4793 Impact factor: 91.245